BCAX Earnings & Financial Statements
Bicara Therapeutics Inc. Common Stock
$17.71
+$0.37(+2.13%)
36
Overall
60
Value
27
Tech
21
Quality
Market Cap
$1.15B
Volume
53.91K
52W Range
$13.70 - $30.99
Target Price
$34.62
BCAX earnings and financial statements: Bicara Therapeutics Inc. Common Stock's income statement, balance sheet and cash flow statement, annual and quarterly.
BCAX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$155.60M | -$82.39M | -$39.89M | -$37.66M |
| EBITDA | -$137.63M | -$67.75M | -$51.96M | -$37.72M |
| Net income | -$137.95M | -$68.00M | -$51.98M | -$37.84M |
| EPS (diluted) | $-2.52 | $-4.05 | $-89.61 | $-88.20 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $430.99M | $510.00M | $233.98M | $6.70M |
| Total liabilities | $29.54M | $18.12M | $15.47M | $23.98M |
| Shareholders’ equity | $401.45M | $491.88M | $53.90M | -$17.28M |
| Cash and equivalents | $96.69M | $489.71M | $230.44M | $4.16M |
| Long-term debt | $593.0K | $131.0K | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$106.83M | -$74.75M | -$59.03M | -$32.08M |
| Capital expenditure | -$280.0K | -$9.0K | - | - |
| Free cash flow | -$107.11M | -$74.82M | -$59.62M | -$32.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCAX | $17.71 | +2.1% | 53.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bicara Therapeutics Inc. Common Stock Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW